Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 1/2012

01.01.2012 | Original Article

Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians

verfasst von: Beth K. Potter, Julian Little, Pranesh Chakraborty, Jonathan B. Kronick, Jessica Evans, Julia Frei, Sarah C. Sutherland, Kumanan Wilson, Brenda J. Wilson

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

There is little robust empirical evidence on which to base treatment recommendations for fatty acid oxidation disorders. While consensus guidelines are important, understanding areas where there is a lack of consensus is also critical to inform priorities for future evaluative research.

Methods

We surveyed Canadian metabolic physicians on the treatment of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, and mitochondrial trifunctional protein (MTP) deficiency. We ascertained physicians’ opinions on the use of different interventions for the long-term management of patients as well as for the management of acute illness, focusing on identifying interventions characterized by high variability in opinions. We also investigated factors influencing treatment decisions.

Results

We received 18 responses (response rate 45%). Participants focused on avoidance of fasting and increased meal frequency as interventions for the management of MCAD deficiency. For the long-chain disorders, avoidance of fasting remained the most consistently endorsed intervention, with additional highly endorsed treatments differing for VLCAD versus LCHAD/MTP deficiency. L-carnitine supplementation and restriction of dietary fat were characterized by high variability in physicians’ opinions, as were several interventions specific to long-chain disorders. Social factors and patient characteristics were important influences on treatment decisions.

Conclusions

Based on our findings we suggest that high priority treatments for rigorous effectiveness studies could include L-carnitine supplementation (MCAD and LCHAD/MTP deficiencies), restriction of dietary fat, and, for the long-chain disorders, feeding practices for breastfed infants and the use of various supplements (essential fatty acids, carbohydrates, cornstarch, multivitamins).
Literatur
Zurück zum Zitat Arnold GL, VanHove J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90PubMedCrossRef Arnold GL, VanHove J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90PubMedCrossRef
Zurück zum Zitat Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA et al. (2010) Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 99:263–268PubMedCrossRef Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA et al. (2010) Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 99:263–268PubMedCrossRef
Zurück zum Zitat Clancy C, Collins FS (2010) Patient-centred outcomes research institute: the intersection of science and health care. Sci Transl Med 2:37cm18 Clancy C, Collins FS (2010) Patient-centred outcomes research institute: the intersection of science and health care. Sci Transl Med 2:37cm18
Zurück zum Zitat Dillman DA (2007) Mail and Internet Surveys. The Tailored Design Method. 2nd ed, 2007 update. New York: Wiley, Inc Dillman DA (2007) Mail and Internet Surveys. The Tailored Design Method. 2nd ed, 2007 update. New York: Wiley, Inc
Zurück zum Zitat Djouadi F, Aubey F, Schlemmer D et al. (2005) Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 14:2695–2703PubMedCrossRef Djouadi F, Aubey F, Schlemmer D et al. (2005) Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 14:2695–2703PubMedCrossRef
Zurück zum Zitat Djouadi F, Aubey F, Schlemmer D et al. (2006) Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? J Inherit Metab Dis 29:341–342PubMedCrossRef Djouadi F, Aubey F, Schlemmer D et al. (2006) Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? J Inherit Metab Dis 29:341–342PubMedCrossRef
Zurück zum Zitat Gillingham MB, Scott B, Elliott D, Harding CO (2006) Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 89:58–63PubMedCrossRef Gillingham MB, Scott B, Elliott D, Harding CO (2006) Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 89:58–63PubMedCrossRef
Zurück zum Zitat Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO (2007) Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 90:64–69PubMedCrossRef Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO (2007) Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 90:64–69PubMedCrossRef
Zurück zum Zitat Griggs RC, Batshaw M, Dunkle M et al. (2009) For the rare diseases clinical research network, Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab 96:20–26PubMedCrossRef Griggs RC, Batshaw M, Dunkle M et al. (2009) For the rare diseases clinical research network, Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab 96:20–26PubMedCrossRef
Zurück zum Zitat Kemper AR, Boyle CA, Aceves J et al. (2008) Long-term follow-up after diagnosis resulting from newborn screening: Statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med 10:259–261PubMedCrossRef Kemper AR, Boyle CA, Aceves J et al. (2008) Long-term follow-up after diagnosis resulting from newborn screening: Statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med 10:259–261PubMedCrossRef
Zurück zum Zitat Laforêt P, Vianey-Saban C (2010) Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 20:693–700PubMedCrossRef Laforêt P, Vianey-Saban C (2010) Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 20:693–700PubMedCrossRef
Zurück zum Zitat Leonard JV (2006) Komrower lecture: Treatment of inborn errors of metabolism: A review. J Inherit Metab Dis 29:275–278PubMedCrossRef Leonard JV (2006) Komrower lecture: Treatment of inborn errors of metabolism: A review. J Inherit Metab Dis 29:275–278PubMedCrossRef
Zurück zum Zitat Nasser M, Javaheri H, Fedorowicz Z, Noorani Z (2009) Carnitine supplementation for inborn errors of metabolism. Cochrane Database of Systematic Reviews. Issue 2. CD006659 Nasser M, Javaheri H, Fedorowicz Z, Noorani Z (2009) Carnitine supplementation for inborn errors of metabolism. Cochrane Database of Systematic Reviews. Issue 2. CD006659
Zurück zum Zitat Roe CR, Sweetman L, Roe DS, David F, Brunengraber H (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110:259–269PubMed Roe CR, Sweetman L, Roe DS, David F, Brunengraber H (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110:259–269PubMed
Zurück zum Zitat Roe CR, Roe DS, Wallace M, Garritson B (2007) Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. Mol Genet Metab 92:346–350PubMedCrossRef Roe CR, Roe DS, Wallace M, Garritson B (2007) Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. Mol Genet Metab 92:346–350PubMedCrossRef
Zurück zum Zitat Solis JO, Singh RH (2002) Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 102:1800–1803PubMedCrossRef Solis JO, Singh RH (2002) Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 102:1800–1803PubMedCrossRef
Zurück zum Zitat Spiekerkoetter U, Lindner M, Santer R et al. (2009a) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498–505PubMedCrossRef Spiekerkoetter U, Lindner M, Santer R et al. (2009a) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498–505PubMedCrossRef
Zurück zum Zitat Spiekerkoetter U, Lindner M, Santer R et al. (2009b) Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 32:488–497PubMedCrossRef Spiekerkoetter U, Lindner M, Santer R et al. (2009b) Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 32:488–497PubMedCrossRef
Zurück zum Zitat Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B (2010) Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 33:555–561PubMedCrossRef Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B (2010) Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 33:555–561PubMedCrossRef
Zurück zum Zitat Steiner RD (2005) Evidence based medicine in inborn errors of metabolism: Is there any and how to find it. Am J Med Genet 134A:192–197PubMedCrossRef Steiner RD (2005) Evidence based medicine in inborn errors of metabolism: Is there any and how to find it. Am J Med Genet 134A:192–197PubMedCrossRef
Zurück zum Zitat VanGeest JB, Johnson TP, Welc VL (2007) Methodologies for improving response rates in surveys of physicians: A systematic review. Eval Health Prof 30:303–321PubMedCrossRef VanGeest JB, Johnson TP, Welc VL (2007) Methodologies for improving response rates in surveys of physicians: A systematic review. Eval Health Prof 30:303–321PubMedCrossRef
Zurück zum Zitat Vockley J, Vockley CMW (2010) Clinical trials: Curing a critical deficiency in metabolic medicine. Mol Genet Metab 99:244–245PubMedCrossRef Vockley J, Vockley CMW (2010) Clinical trials: Curing a critical deficiency in metabolic medicine. Mol Genet Metab 99:244–245PubMedCrossRef
Zurück zum Zitat Walter JH (2003) L-carnitine in inborn errors of metabolism: what is the evidence? J Inherit Metab Dis 26:181–188PubMedCrossRef Walter JH (2003) L-carnitine in inborn errors of metabolism: what is the evidence? J Inherit Metab Dis 26:181–188PubMedCrossRef
Zurück zum Zitat Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33:501–506PubMedCrossRef Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33:501–506PubMedCrossRef
Zurück zum Zitat Wilcken B, Haas M, Joy P et al. (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37–42PubMedCrossRef Wilcken B, Haas M, Joy P et al. (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37–42PubMedCrossRef
Metadaten
Titel
Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians
verfasst von
Beth K. Potter
Julian Little
Pranesh Chakraborty
Jonathan B. Kronick
Jessica Evans
Julia Frei
Sarah C. Sutherland
Kumanan Wilson
Brenda J. Wilson
Publikationsdatum
01.01.2012
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 1/2012
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-011-9352-2

Weitere Artikel der Ausgabe 1/2012

Journal of Inherited Metabolic Disease 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.